Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Year: 2019
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Hironobu Hashimoto, Masakazu Abe, Osamu Tokuyama, Hideaki Mizutani, Yosuke Uchitomi, Takuhiro Yamaguchi, Yukari Hoshina, Yasuhiko Sakata, Takako Yanai Takahashi, Kazuhisa Nakashima, Masahiko Nakao, Daisuke Takei, Sadamoto Zenda, Koki Mizukami, Satoru Iwasa, Michiru Sakurai, Noboru Yamamoto, Yuichiro Ohe
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: olanzapine, chemotherapy-induced nausea and vomiting, antiemetic prophylaxis, cisplatin, aprepitant, palonosetron, dexamethasone, dose reduction, sedation, highly emetogenic chemotherapy, complete response, antipsychotic drugs, cancer patients, Japan, Eastern Cooperative Oncology Group performance status
Open Access status: closed
Awards: Development of a question prompting and decision-making mobile intervention to facilitate patients' communication towards their final stages of cancer: a randomized controlled trial, Physician's behaviors and cancer patient's trust, シスプラチンを含む高度催吐性化学療法による化学療法誘発性悪心・嘔吐の予防に対する標準制吐療法+オランザピンの有効性と安全性を比較する二重盲検プラセボ対照第3相ランダム化比較試験
OpenAlex ID: W2996099006
